| Name | Title | Contact Details |
|---|
BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
Opexa Therapeutics is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch`s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn`s disease, respectively.
Meso Scale Discovery is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Legacy Health System is an Oregon-based not-for-profit, tax-exempt corporation that includes five full-service hospitals and a children's hospital.